Page 3 - Eye Condition News Today

Started, one of the big issues was how do you get those genes into people? so we, and others, over the last five to ten years, have developed a new viral vector, and were manufacturing that here to deliver the genes were delivering into the body. in addition, at meira, weve actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place h...

Here to deliver the genes were delivering into the body. in addition, at meira, weve actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to eventually lose vision. ...

Becoming incorrectly switched on, this treatment tries to turn it off — or vice versa. when the idea of gene therapy started, one of the big issues was, how do you get those genes into people? so we, and others, over the last five to ten years, have developed a new viral vector, and were manufacturing that here to deliver the genes were delivering into the body. in addition, at meira, weve actually developed, over the last seven years, a totally new technology which allows us to, in the future...

That here to deliver the genes were delivering into the body. in addition, at meira, weve actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to eventually lose vis...

In addition, at meira, weve actually developed over the last seven years a totally new technology which allows us to, in the future, control how those genes that are delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells and green are the cone cells...

Where disease is caused by a gene becoming incorrectly switched on, this treatment tries to turn it off or vice versa. when the idea of gene therapy started, one of the big issues was — how do you get those genes into people? so we and others, over the last five to ten years, have developed a new viral vector, and were manufacturing that here to deliver the genes were delivering into the body. in addition, at meira, weve actually developed over the last seven years a totally new technology whi...

And were manufacturing that here to deliver the genes were delivering into the body. in addition, at meira, weve actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person...

Weve actually developed over the last seven years a totally new technology which allows us to, in the future, control how those genes are delivered to the body, are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells and green are the cone cells, so they exist in this kin...

One of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells are the cone cells, so they exist in this kind of mosaic. early results of using gene therapy to treat retinitis pigmentosa has shown that it could potentially not only slow the progression of the disease, but, in some cases, reverse some of i...

So we and others, over the last five to ten years, have developed a new viral vector, and were manufacturing that here to deliver the genes were delivering into the body. in addition, at meira, weve actually developed over the last seven years a totally new technology which allows us to, in the future, control how those genes that are delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmento...